In light of the promising clinical efficacy and safety that has been reported, it is anticipated that mTOR inhibitors such as sirolimus and everolimus can be an effective treatment option in TSC, and have the potential to be a disease-modifying therapy in patients with the disease. This evidence concerns the gene MTOR and tuberous sclerosis.